DPP-4 Inhibitor and Sulfonylurea Differentially Reverse Type 2 Diabetes-Induced Blood-Brain Barrier Leakage and Normalize Capillary Pericyte Coverage.

Publication Year: 2023

DOI:
10.2337/db22-0674

PMCID:
PMC9935496

PMID:
36448982

Journal Information

Full Title: Diabetes

Abbreviation: Diabetes

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Endocrinology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Duality of Interest. This study received funding from Boehringer Ingelheim Pharma GmbH & Co. KG. T.K. is employed at Boehringer Ingelheim Pharma GmbH & Co. KG."

Evidence found in paper:

"Funding. This work was mainly supported by the Swedish Parkinson Foundation and the Åhlens Foundation and by an award from Boehringer Ingelheim Pharma GmbH & Co. KG (to C.P.), Financial support was also provided by Hjärnfonden, Diabetesfonden, Ulla Hamberg Angeby och Lennart Angebys Stiftelse, the Swedish Stroke Foundation, the Swedish Heart-Lung Foundation, and by the ALF regional agreement on medical training and clinical research."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025